Efficacy of papaverine addition for treatment-refractory major depression.
Malison
R T
RT
Price
L H
LH
Nestler
E J
EJ
Heninger
G R
GR
Duman
R S
RS
D002065:Buspirone / Q000627:therapeutic use; D003511:Cyclohexanols / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D008875:Middle Aged; D010208:Papaverine / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D000069470:Venlafaxine Hydrochloride
D002065:Buspirone; D003511:Cyclohexanols; D008094:Lithium; D010208:Papaverine; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride